The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment
Abstract
Cancer treatment by conventional chemotherapy is hindered by toxic side effects and the frequent development of multi-drug resistance by cancer cells. Cationic antimicrobial peptides (CAPs) are a promising new class of natural-source drugs that may avoid the shortcomings of conventional chemotherapy because certain CAPs exhibit selective cytotoxicity against a broad spectrum of human cancer cells, including neoplastic cells that have acquired a multi-drug-resistant phenotype. Tumour cell killing by CAPs is usually by a cell membrane-lytic effect, although some CAPs can trigger apoptosis in cancer cells via mitochondrial membrane disruption. Furthermore, certain CAPs are potent inhibitors of blood vessel development (angiogenesis) that is associated with tumour progression. This article reviews the mechanisms by which CAPs exert anticancer activity and discusses the potential application of selected CAPs as therapeutic agents for the treatment of human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antimicrobial peptides of multicellular organisms
Zasloff, M. (2002) · Nature · doi:10.1038/415389a · Cited by 8,457
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · cited 1×
“Furthermore, cancer cells frequently develop resistance to many anticancer drugs, which greatly reduces their therapeutic usefulness [5,6].”
BackgroundProgress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501
Zasloff, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.15.5449 · Cited by 2,305
Gray, M. W., Burger, G., & Lang, B. F. (1999) · Science · doi:10.1126/science.283.5407.1476 · Cited by 1,719
Sequence and specificity of two antibacterial proteins involved in insect immunity
Steiner, H., Hultmark, D., Engström, Å., Bennich, H., & Boman, H. G. (1981) · Nature · doi:10.1038/292246a0 · Cited by 1,427
Cathelicidins, multifunctional peptides of the innate immunity
Zanetti, M. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0403147 · Cited by 988 · cited 8×
“In addition, human hepatocellular carcinoma cells engineered to express porcine PR-39 (which is a proline-rich rather than a α-helical cathelicidin) exhibit altered actin structure and reduced invasive activity, suggesting gene therapy with PR-39 as a possible approach to inhibiting tumour cell metastasis [49].”
BackgroundInfluentialThe relationship between peptide structure and antibacterial activity
Powers, J.-P. S., & Hancock, R. E. W. (2003) · Peptides · doi:10.1016/j.peptides.2003.08.023 · Cited by 948
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
Sengupta, S., Eavarone, D., Capila, I., Zhao, G., Watson, N., Kiziltepe, T., & Sasisekharan, R. (2005) · Nature · doi:10.1038/nature03794 · Cited by 945
Cited by
Studies on anticancer activities of antimicrobial peptides
Hoskin, D. W., & Ramamoorthy, A. (2008) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.11.008 · Cited by 1,296
Self-citationKumar, P., Kizhakkedathu, J., & Straus, S. (2018) · Biomolecules · doi:10.3390/biom8010004 · Cited by 1,227
From antimicrobial to anticancer peptides. A review
Gaspar, D., Veiga, A. S., & Castanho, M. A. R. B. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00294 · Cited by 749
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Multifunctional cationic host defence peptides and their clinical applications
Yeung, A. T. Y., Gellatly, S. L., & Hancock, R. E. W. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0710-x · Cited by 610
Immune modulation by multifaceted cationic host defense (antimicrobial) peptides
Hilchie, A. L., Wuerth, K., & Hancock, R. E. W. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1393 · Cited by 601
Antimicrobial peptides: Promising alternatives in the post feeding antibiotic era
Wang, J., Dou, X., Song, J., Lyu, Y., Zhu, X., Xu, L., Li, W., & Shan, A. (2019) · Medicinal Research Reviews · doi:10.1002/med.21542 · Cited by 547
Mookherjee, N., & Hancock, R. E. W. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6475-6 · Cited by 462
Wei, L., Zhou, C., Chen, H., Song, J., & Su, R. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty451 · Cited by 439
iACP: a sequence-based tool for identifying anticancer peptides
Chen, W., Ding, H., Feng, P., Lin, H., & Chou, K.-C. (2016) · Oncotarget · doi:10.18632/oncotarget.7815 · Cited by 433
Antimicrobial Peptides: Primeval Molecules or Future Drugs?
Peters, B. M., Shirtliff, M. E., & Jabra-Rizk, M. A. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001067 · Cited by 425
Riedl, S., Zweytick, D., & Lohner, K. (2011) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2011.09.004 · Cited by 405
CancerPPD: a database of anticancer peptides and proteins
Tyagi, A., Tuknait, A., Anand, P., Gupta, S., Sharma, M., Mathur, D., Joshi, A., Singh, S., Gautam, A., & Raghava, G. P. S. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku892 · Cited by 397
Peptides with Dual Antimicrobial and Anticancer Activities
Felício, M. R., Silva, O. N., Gonçalves, S., Santos, N. C., & Franco, O. L. (2017) · Frontiers in Chemistry · doi:10.3389/fchem.2017.00005 · Cited by 393
Cell-penetrating peptides as delivery vehicles for biology and medicine
Stewart, K. M., Horton, K. L., & Kelley, S. O. (2008) · Organic & Biomolecular Chemistry · doi:10.1039/b719950c · Cited by 381
AntiCP 2.0: an updated model for predicting anticancer peptides
Agrawal, P., Bhagat, D., Mahalwal, M., Sharma, N., & Raghava, G. P. S. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa153 · Cited by 345
In Silico Models for Designing and Discovering Novel Anticancer Peptides
Tyagi, A., Kapoor, P., Kumar, R., Chaudhary, K., Gautam, A., & Raghava, G. P. S. (2013) · Scientific Reports · doi:10.1038/srep02984 · Cited by 320
Cicero, A. F. G., Fogacci, F., & Colletti, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13608 · Cited by 317
Peptide-based cancer therapy: Opportunity and challenge
Wu, D., Gao, Y., Qi, Y., Chen, L., Ma, Y., & Li, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.05.002 · Cited by 306
Characterization of Antimicrobial Peptides toward the Development of Novel Antibiotics
Aoki, W., & Ueda, M. (2013) · Pharmaceuticals · doi:10.3390/ph6081055 · Cited by 252
Bacteriocins: Perspective for the development of novel anticancer drugs
Baindara, P., Korpole, S., & Grover, V. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9420-8 · Cited by 139
Metadata
- Authors
- Mader, J. S., & Hoskin, D. W.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2006-07-21
- Volume
- 15
- Issue
- 8
- Pages
- 933-946
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2103567156
- Cited by
- 430
- References
- 100
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.